Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Presents Results Showing That Carriers of an LPA Gene Variant are at Elevated Risk of CHD Among Non-users of Aspirin, but not Among Aspirin Users


ALAMEDA, CA - April 29, 2009

Celera Corporation (NASDAQ:CRA) and its collaborators at The University of Texas, Baylor College of Medicine, and Brigham and Women’s Hospital, today reported that, among non-users of aspirin, those who carry an LPA gene variant were at increased risk of coronary heart disease (CHD), compared with noncarriers. Carriers of the LPA variant were not at increased risk among those who use aspirin. This study was conducted among the middle aged Caucasian men and women of the ARIC study. These results were presented today at the 2009 Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference under the auspices of the American Heart Association in Washington, DC.

The current study is consistent with previous findings(1) from the Women’s Health Study, a randomized trial of aspirin and placebo, where carriers of this LPA gene variant when compared with noncarriers, had over 2 fold increased risk for major cardiovascular events in the placebo group, an excess risk that was essentially eliminated by low-dose aspirin therapy.

Recent studies indicate that the LPA gene variant is a new, independent predictor of risk for CHD in men and women(2-4) and clinical benefit from aspirin therapy in women(1). LPA encodes apolipoprotein(a), a protein component of Lp(a) plasma lipoprotein particles, and the gene variant results in an amino acid substitution (methionine for isoleucine) in the protease-like domain of apolipoprotein(a). Approximately 3.5% of Caucasians in studied populations are carriers of the LPA gene variant, and these carriers have also been found to have higher levels of plasma Lp(a) levels.

Study Details
Findings from the current study were based on analysis of 6,752 Caucasian participants in the Atherosclerosis Risk in Communities (ARIC) Study, a large-scale, long-term prospective study that is being conducted to investigate established and suspected CHD risk factors in middle aged American men and women. During a median follow-up of 7.2 years after aspirin use information was collected, 636 (9.4%) of the participants in this study had a first incident CHD event. After adjusting for age and sex, the hazard ratio for CHD among 5,330 non-users of aspirin was 1.57 (for carriers of the LPA gene variant compared with noncarriers); the hazard ratio of 0.86 among 1,422 aspirin users. “This study indicates that carriers of the LPA gene variant are both at higher risk of cardiovascular disease and that this risk is not observed among users of aspirin,” said Eric Boerwinkle, Ph.D., Professor and Center Director, Human Genetics Center at the University of Texas, and senior author of the abstract. “These data could provide a genetic method for defining subpopulations with differential benefit from aspirin therapy for prevention of coronary heart disease.”

“We believe this supporting evidence for our previous findings regarding the LPA gene variant in a population that includes aspirin treatment information in both men and women is an important step toward demonstrating the clinical utility among different segments of the population,” said Thomas White, Ph.D., Chief Scientific Officer at Celera. “We believe these findings make a compelling case for testing for LPA status, and further our commitment to be a leading provider of genetic tests used routinely in personalizing disease management.”

About Celera
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at

Forward-Looking Statements - Celera
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "plan," and "could," among others. These forward-looking statements are based on Celera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Celera notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) Celera is using novel and unproven methods to discover markers for the development of new diagnostic products, which may not be successful; (2) the diagnostic industry is very competitive, and new diagnostic products may not be accepted and adopted by the market; (3) demand for diagnostic products may be adversely affected if users of these products cannot receive adequate reimbursement for these products from third party payors such as private insurance companies and government insurance plans; (4) potential product liability or other claims against Celera as a result of the testing or use of its products; and (5) uncertainty of the availability to Celera of intellectual property protection, limitations on its ability to protect trade secrets, the risk to it of infringement claims, and the possibility that it may need to license intellectual property from third parties to avoid or settle such claims. The foregoing list sets forth some, but not all, of the factors that could affect Celera's ability to achieve results described in any forward-looking statements. For additional information about the risks and uncertainties that Celera faces and a discussion of its financial statements and footnotes, see documents filed by Celera with the SEC, including its transition report on Form 10-KT and all subsequent periodic reports. All information in this press release is as of the date of the release, and Celera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Copyright© 2009. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.

Selected references
1 Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis, 2009; 203:371–6.

2 Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2030-6.

3 Shiffman D, Kane JP, Louie JZ, et al. Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction. PLoS ONE 2008; 3:e2895.

3 Shiffman D, O’Meara ES, Bare LA, et al. Association of gene variants with incident myocardial infarction in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2008; 28:173-9.


David Speechly, Ph.D.
+1 (510) 749-1853

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.